Trial Profile
Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Oct 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.
- 18 Sep 2019 Status changed from recruiting to active, no longer recruiting.